296 related articles for article (PubMed ID: 20228274)
21. Lentiviral Gene Therapy Combined with Low-Dose Busulfan in Infants with SCID-X1.
Mamcarz E; Zhou S; Lockey T; Abdelsamed H; Cross SJ; Kang G; Ma Z; Condori J; Dowdy J; Triplett B; Li C; Maron G; Aldave Becerra JC; Church JA; Dokmeci E; Love JT; da Matta Ain AC; van der Watt H; Tang X; Janssen W; Ryu BY; De Ravin SS; Weiss MJ; Youngblood B; Long-Boyle JR; Gottschalk S; Meagher MM; Malech HL; Puck JM; Cowan MJ; Sorrentino BP
N Engl J Med; 2019 Apr; 380(16):1525-1534. PubMed ID: 30995372
[TBL] [Abstract][Full Text] [Related]
22. Hot spots of retroviral integration in human CD34+ hematopoietic cells.
Cattoglio C; Facchini G; Sartori D; Antonelli A; Miccio A; Cassani B; Schmidt M; von Kalle C; Howe S; Thrasher AJ; Aiuti A; Ferrari G; Recchia A; Mavilio F
Blood; 2007 Sep; 110(6):1770-8. PubMed ID: 17507662
[TBL] [Abstract][Full Text] [Related]
23. Intravenous injection of a foamy virus vector to correct canine SCID-X1.
Burtner CR; Beard BC; Kennedy DR; Wohlfahrt ME; Adair JE; Trobridge GD; Scharenberg AM; Torgerson TR; Rawlings DJ; Felsburg PJ; Kiem HP
Blood; 2014 Jun; 123(23):3578-84. PubMed ID: 24642749
[TBL] [Abstract][Full Text] [Related]
24. Insertional mutagenesis by retroviral vectors: current concepts and methods of analysis.
Knight S; Collins M; Takeuchi Y
Curr Gene Ther; 2013 Jun; 13(3):211-27. PubMed ID: 23590635
[TBL] [Abstract][Full Text] [Related]
25. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1.
Hacein-Bey-Abina S; Von Kalle C; Schmidt M; McCormack MP; Wulffraat N; Leboulch P; Lim A; Osborne CS; Pawliuk R; Morillon E; Sorensen R; Forster A; Fraser P; Cohen JI; de Saint Basile G; Alexander I; Wintergerst U; Frebourg T; Aurias A; Stoppa-Lyonnet D; Romana S; Radford-Weiss I; Gross F; Valensi F; Delabesse E; Macintyre E; Sigaux F; Soulier J; Leiva LE; Wissler M; Prinz C; Rabbitts TH; Le Deist F; Fischer A; Cavazzana-Calvo M
Science; 2003 Oct; 302(5644):415-9. PubMed ID: 14564000
[TBL] [Abstract][Full Text] [Related]
26. Long-term vector integration site analysis following retroviral mediated gene transfer to hematopoietic stem cells for the treatment of HIV infection.
Hayakawa J; Washington K; Uchida N; Phang O; Kang EM; Hsieh MM; Tisdale JF
PLoS One; 2009; 4(1):e4211. PubMed ID: 19148292
[TBL] [Abstract][Full Text] [Related]
27. Comparison of HIV-derived lentiviral and MLV-based gammaretroviral vector integration sites in primate repopulating cells.
Beard BC; Dickerson D; Beebe K; Gooch C; Fletcher J; Okbinoglu T; Miller DG; Jacobs MA; Kaul R; Kiem HP; Trobridge GD
Mol Ther; 2007 Jul; 15(7):1356-65. PubMed ID: 17440443
[TBL] [Abstract][Full Text] [Related]
28. Retrovirus-induced oncogenesis and safety of retroviral vectors.
Nair V
Curr Opin Mol Ther; 2008 Oct; 10(5):431-8. PubMed ID: 18830918
[TBL] [Abstract][Full Text] [Related]
29. Nuclease-free Adeno-Associated Virus-Mediated Il2rg Gene Editing in X-SCID Mice.
Hiramoto T; Li LB; Funk SE; Hirata RK; Russell DW
Mol Ther; 2018 May; 26(5):1255-1265. PubMed ID: 29606506
[TBL] [Abstract][Full Text] [Related]
30. Potential genotoxicity from integration sites in CLAD dogs treated successfully with gammaretroviral vector-mediated gene therapy.
Hai M; Adler RL; Bauer TR; Tuschong LM; Gu YC; Wu X; Hickstein DD
Gene Ther; 2008 Jul; 15(14):1067-71. PubMed ID: 18369320
[TBL] [Abstract][Full Text] [Related]
31. Retroviral integration sites correlate with expressed genes in hematopoietic stem cells.
Wagner W; Laufs S; Blake J; Schwager C; Wu X; Zeller JW; Ho AD; Fruehauf S
Stem Cells; 2005 Sep; 23(8):1050-8. PubMed ID: 16140869
[TBL] [Abstract][Full Text] [Related]
32. Lentiviral hematopoietic stem cell gene therapy for X-linked severe combined immunodeficiency.
De Ravin SS; Wu X; Moir S; Anaya-O'Brien S; Kwatemaa N; Littel P; Theobald N; Choi U; Su L; Marquesen M; Hilligoss D; Lee J; Buckner CM; Zarember KA; O'Connor G; McVicar D; Kuhns D; Throm RE; Zhou S; Notarangelo LD; Hanson IC; Cowan MJ; Kang E; Hadigan C; Meagher M; Gray JT; Sorrentino BP; Malech HL; Kardava L
Sci Transl Med; 2016 Apr; 8(335):335ra57. PubMed ID: 27099176
[TBL] [Abstract][Full Text] [Related]
33. Gene therapy for severe combined immunodeficiencies.
Gaspar HB; Thrasher AJ
Expert Opin Biol Ther; 2005 Sep; 5(9):1175-82. PubMed ID: 16120048
[TBL] [Abstract][Full Text] [Related]
34. Gene therapy for severe combined immunodeficiencies and beyond.
Fischer A; Hacein-Bey-Abina S
J Exp Med; 2020 Jan; 217(2):. PubMed ID: 31826240
[TBL] [Abstract][Full Text] [Related]
35. Retroviral Insertional Mutagenesis in Humans: Evidence for Four Genetic Mechanisms Promoting Expansion of Cell Clones.
Bushman FD
Mol Ther; 2020 Feb; 28(2):352-356. PubMed ID: 31951833
[TBL] [Abstract][Full Text] [Related]
36. Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity.
Modlich U; Bohne J; Schmidt M; von Kalle C; Knöss S; Schambach A; Baum C
Blood; 2006 Oct; 108(8):2545-53. PubMed ID: 16825499
[TBL] [Abstract][Full Text] [Related]
37. Long-term clinical and molecular follow-up of large animals receiving retrovirally transduced stem and progenitor cells: no progression to clonal hematopoiesis or leukemia.
Kiem HP; Sellers S; Thomasson B; Morris JC; Tisdale JF; Horn PA; Hematti P; Adler R; Kuramoto K; Calmels B; Bonifacino A; Hu J; von Kalle C; Schmidt M; Sorrentino B; Nienhuis A; Blau CA; Andrews RG; Donahue RE; Dunbar CE
Mol Ther; 2004 Mar; 9(3):389-95. PubMed ID: 15006605
[TBL] [Abstract][Full Text] [Related]
38. Integration profile of retroviral vector in gene therapy treated patients is cell-specific according to gene expression and chromatin conformation of target cell.
Biasco L; Ambrosi A; Pellin D; Bartholomae C; Brigida I; Roncarolo MG; Di Serio C; von Kalle C; Schmidt M; Aiuti A
EMBO Mol Med; 2011 Feb; 3(2):89-101. PubMed ID: 21243617
[TBL] [Abstract][Full Text] [Related]
39. Insertional mutagenesis and clonal dominance: biological and statistical considerations.
Fehse B; Roeder I
Gene Ther; 2008 Jan; 15(2):143-53. PubMed ID: 17972922
[TBL] [Abstract][Full Text] [Related]
40. [Gene therapy using retrovirus vectors: vector development and biosafety at clinical trials].
Doi K; Takeuchi Y
Uirusu; 2015; 65(1):27-36. PubMed ID: 26923955
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
